Annual Review of Cancer Biology

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Retrieved on: 
Tuesday, October 10, 2023
ADMAR, Cystic Fibrosis Foundation, MBA, Doctor of Philosophy, Research, Pregnancy specific biological substances, G.H. Raisoni Department of Microbiology and Biotechnology, Bristol Myers Squibb, Berkeley, MD, Master of Science, Organization, Therapy, Liver, Genetics, University, Mutation, Rachel Haurwitz, Disease, University of Miami Division of Surgical Neurooncology, Arrowhead Pharmaceuticals, Leonard M. Miller School of Medicine, Cystic fibrosis, Annual Review of Cancer Biology, University of Virginia Cancer Center, Acute leukemia, DSM-IV codes, Gene editing, Astex Pharmaceuticals, Specific, Dasatinib, CNS, Patient, Vaccine, Pharmaceutical industry, Investment, Microbiology, Immunology

Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.

Key Points: 
  • Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.
  • TORONTO, Oct. 10, 2023 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Steven Kanner, PhD, as an Independent Director.
  • The appointment coincides with renewed investment from Lumira Ventures and adMare BioInnovations to advance the preclinical development of therapeutics based on Specific's proprietary Dualase® platform gene editors.
  • The additional investment from Lumira Ventures and adMare BioInnovations will be used to advance preclinical testing of Dualase gene editors in liver, ocular and CNS disorders.

Senda Biosciences Appoints Igor Matushansky as Chief Medical Officer

Retrieved on: 
Monday, July 24, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Columbia University, Memorial Sloan Kettering Cancer Center, Gene, Sarcoma, Columbia University Irving Medical Center, Arenavirus, Weill Cornell Medical Center, Doctor of Philosophy, Molecular biology, Weill Cornell Medicine, Flagship Pioneering, Novartis, MD, Patient, NewYork-Presbyterian Hospital, Daiichi Sankyo, Cell, Albert Einstein College of Medicine, Pharmaceutical industry, Annual Review of Cancer Biology, IND

Senda Biosciences, Inc. , a Flagship Pioneering company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Igor Matushansky, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Senda Biosciences, Inc. , a Flagship Pioneering company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Igor Matushansky, M.D., Ph.D., as Chief Medical Officer.
  • Dr. Matushansky will also serve as an Oncology Senior Advisor for Pioneering Medicines, a unit within Flagship Pioneering.
  • “I’m delighted to welcome Igor on board as Senda’s first Chief Medical Officer, as we accelerate our efforts to build out our groundbreaking pipeline of programmable medicines,” said Guillaume Pfefer, Ph.D., Chief Executive Officer, Senda Biosciences and CEO-Partner, Flagship Pioneering.
  • “I’m delighted to join the exceptionally talented team at Senda,” said Dr. Matushansky.

X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 4, 2023
CIS, Doctor of Philosophy, Associate, Icahn School of Medicine at Mount Sinai, X4, MD, WHIM syndrome, Patient, Translational research, Cell, Research and development, R, University, University of Massachusetts, Therapy, WHIM, Host, Wart, Immunology, Hospital, Rare, Pediatric Blood & Cancer, Safety, Abstract, Conference call, Rheumatology, Mount Sinai, ID, Immune system, Duke University School of Medicine, Federation of Clinical Immunology Societies, Annual Review of Cancer Biology, Restricted, ANC, SG, Clinical trial, Harvard Medical School, State Administrative Expenses, Annual general meeting, Upcoming, Pharmaceutical industry, Medical imaging, Dentistry, Management, Myelokathexis, Pediatrics, Conference, Hypogammaglobulinemia, Infection, Medicine

BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2023 and highlighted key upcoming expected milestones.

Key Points: 
  • “This is an exciting time at X4 as we look forward to delivering on several expected major milestones throughout the rest of 2023,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • Cash, Cash Equivalents & Restricted Cash: X4 had $94.4 million in cash, cash equivalents, and restricted cash as of March 31, 2023.
  • X4 will host a conference call and webcast today at 8:30 am ET to discuss these financial results and business highlights.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

Don't Confuse Monkeypox with This Medical Condition That Affects Over 250,000 People

Retrieved on: 
Thursday, September 8, 2022
University, University of Pittsburgh Medical Center, Monkeypox, Medicine, Research, Washington University School of Medicine, Parent, Skin, Diagnosis, Foundation, Nerve, Mental health, Neoplasm, NF1, Face, Annual Review of Cancer Biology, Learning difficulties, Torso, Family, Social media, Medical imaging, Pharmaceutical industry, MD, Dermatology, Neurofibromatosis

DUNCANSVILLE, Pa., Sept. 8, 2022 /PRNewswire/ -- There is a growing trend on social media to publicly shame individuals with visible bumps and raised tumors, and immediately assume the individual has Monkeypox. However, that isn't true. Approximately 250,000 people worldwide have a condition call NF1, or Neurofibromatosis, a genetic condition which causes small tumors to grow on nerve endings, creating fleshy bumps on and underneath the skin.

Key Points: 
  • Approximately 250,000 people worldwide have a condition call NF1, or Neurofibromatosis, a genetic condition which causes small tumors to grow on nerve endings, creating fleshy bumps on and underneath the skin.
  • Monkeypox is characterized by painful, hard or pus-filled lesions on the skin that actually scab and fall off.
  • At age 5, a neurologist finally diagnosed Giorgio with a rare condition, neurofibromatosis type 1 or NF1.
  • "We partner with researchers that have a proven record of modeling NF1 and progressing existing research of the condition.

Adela Announces Executive and Board of Directors Appointments and Formation of Scientific Advisory Board

Retrieved on: 
Monday, May 23, 2022
Capital, Disease, Stanford University, Research, Epidemiology, Hotel manager, University, Adela Investment Company, Cancer, SAB, Oncology, Master of Science, Knight Cancer Institute, UCL, Annual Review of Cancer Biology, Peter MacCallum Cancer Centre, Medical statistics, University College London, Cellular Dynamics International, Genomic Health, Board, Celebrity board director, Exact sciences, Department, DNA, Genome, Doctor of Philosophy, Multimedia, MBBS, Leukemia Research, Affymetrix, Leukemia, Machine learning, Coronavirus Scientific Advisory Board (Turkey), Assistant, Business development, View, Cancer research, Marker beacon, Dean (education), RA, MS, Genomics, Technology, Board of directors, Diagnosis, CEO, Management, Radiology, Professor, Medicine, FRACP, MD

TORONTO, May 23, 2022 /PRNewswire/ -- Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has made appointments to the Executive Team and Board of Directors that add to the deep industry and scientific expertise of the current team. The company has also formed a Scientific Advisory Board comprised of renowned scientists and clinicians.

Key Points: 
  • The company has also formed a Scientific Advisory Board comprised of renowned scientists and clinicians.
  • "I am thrilled to welcome Chris Parker, Chief Business Officer to Adela's Executive Team," said Scott Bratman, Chief Executive Officer at Adela.
  • Chris Parker joins Adela from Exact Sciences, where he served as Vice President, Business Development and was responsible for inorganic growth strategy.
  • Adela has also formed a Scientific Advisory Board (SAB) with deep expertise in cancer biology, machine learning, and cancer screening.